-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] The Chinese medicine sector has been trending strongly in the past year.
According to statistics, from mid-March to the end of the month, a total of 68 Chinese medicine stocks rebounded and rose, including Panlong Pharmaceutical, Guizhou Bailing, Essence Pharmaceutical, Longjin Pharmaceutical, etc.
.
Among them, the market of Panlong Pharmaceutical is improving, recording 10 boards in 12 days, an increase of nearly 129% during the period
.
As of the close on March 31, Panlong Pharmaceutical closed at 62.
04 yuan, down 8.
29%, with a turnover rate of 47.
61%, a trading volume of 263,300 lots, and a turnover of 1.
789 billion yuan
.
For the reasons for the continuous daily limit of the stock, industry analysts believe that it is mainly related to the concept of traditional Chinese medicine and the concept of new crown drugs
.
According to public information, Panlong Pharmaceutical is a traditional Chinese medicine enterprise integrating GAP cultivation of medicinal materials, drug production, research and development, sales and pharmaceutical logistics as its core industries
.
On March 16, the company replied to investors on the investor interaction platform that the company's product "Qingwen Hufei Granules" was an in-hospital preparation of traditional Chinese medicine declared and approved by the Shaanxi Academy of Traditional Chinese Medicine for the prevention and treatment of new coronary pneumonia.
The Medical Research Institute signed a strategic cooperation agreement
.
On March 17, the company announced that its "Coronavirus 3CL Protease Inhibitor Development" project has been submitted to the "2021 Second Batch of Key Core Technology Industrialization "Revelation and Command" projects jointly issued by the Shaanxi Provincial Department of Industry and Information Technology and the Department of Finance.
The 3CL protease inhibitors and PROTACs synthesized in this project have applied for patents in China, the United States, Japan and other countries, and a patent pool of anti-new coronavirus drugs has been initially constructed, which is still in the preclinical research stage
.
Up to now, the company has not disclosed the 2021 annual report.
According to the 2021 third quarter report released by Panlong Pharmaceutical, the company achieved a total operating income of 623 million yuan in the first three quarters of 2021, a year-on-year increase of 37.
97%; realized a net profit of 73 million yuan, a year-on-year increase.
an increase of 10.
74%
.
According to the company's 2021 performance forecast data, it is expected to achieve a net profit of 87 million yuan to 97 million yuan for the year, with a year-on-year change range of 9.
97% to 22.
61%
.
As for the reasons for the changes in performance, Panlong Pharmaceutical said that it was mainly due to the increase in sales of the company's self-produced products and the increase in income from the pharmaceutical distribution business
.
In addition to Panlong Pharmaceutical, Guizhou Bailing, Essence Pharmaceutical and other stocks also performed well, with an increase of more than 50%, and the daily limit exceeded 4 times during the period
.
It is understood that from the beginning of 2021 to March 28, 2022, the Chinese Medicine Index (CITIC) increased by 18.
5%, while the overall pharmaceutical index (CITIC) fell by 16.
5% during the same period.
It has become the sub-sector with the largest increase in the pharmaceutical sector
.
In 2022, favorable policies will continue to inject new impetus into the development of traditional Chinese medicine
.
On March 29, the "14th Five-Year Plan" was released, and 10 key tasks were deployed for the work of traditional Chinese medicine during the "14th Five-Year Plan" period
.
Compared with the previous policy, it is more detailed and more maneuverable
.
In this regard, Huaan Securities released a research report pointing out that the Chinese medicine industry has undergone changes driven by the "14th Five-Year Plan" policy
.
CITIC Securities said 2022 will be a critical year for investment in the traditional Chinese medicine sector
.
The market of traditional Chinese medicine is sustainable
.
The agency stated that continuous policy encouragement (including the "14th Five-Year" Chinese Medicine Development Plan announced in March 2022) has brought a relatively certain market space for the release of Chinese medicine companies' performance
.
The mild expectation of the decline in the centralized procurement of Chinese patent medicines, the market expansion of Chinese medicine formula granules, and the positive signals of supporting the innovative development of Chinese medicine from the payment side are expected to bring greater performance flexibility to some leading Chinese medicine companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
According to statistics, from mid-March to the end of the month, a total of 68 Chinese medicine stocks rebounded and rose, including Panlong Pharmaceutical, Guizhou Bailing, Essence Pharmaceutical, Longjin Pharmaceutical, etc.
.
Among them, the market of Panlong Pharmaceutical is improving, recording 10 boards in 12 days, an increase of nearly 129% during the period
.
As of the close on March 31, Panlong Pharmaceutical closed at 62.
04 yuan, down 8.
29%, with a turnover rate of 47.
61%, a trading volume of 263,300 lots, and a turnover of 1.
789 billion yuan
.
For the reasons for the continuous daily limit of the stock, industry analysts believe that it is mainly related to the concept of traditional Chinese medicine and the concept of new crown drugs
.
According to public information, Panlong Pharmaceutical is a traditional Chinese medicine enterprise integrating GAP cultivation of medicinal materials, drug production, research and development, sales and pharmaceutical logistics as its core industries
.
On March 16, the company replied to investors on the investor interaction platform that the company's product "Qingwen Hufei Granules" was an in-hospital preparation of traditional Chinese medicine declared and approved by the Shaanxi Academy of Traditional Chinese Medicine for the prevention and treatment of new coronary pneumonia.
The Medical Research Institute signed a strategic cooperation agreement
.
On March 17, the company announced that its "Coronavirus 3CL Protease Inhibitor Development" project has been submitted to the "2021 Second Batch of Key Core Technology Industrialization "Revelation and Command" projects jointly issued by the Shaanxi Provincial Department of Industry and Information Technology and the Department of Finance.
The 3CL protease inhibitors and PROTACs synthesized in this project have applied for patents in China, the United States, Japan and other countries, and a patent pool of anti-new coronavirus drugs has been initially constructed, which is still in the preclinical research stage
.
Up to now, the company has not disclosed the 2021 annual report.
According to the 2021 third quarter report released by Panlong Pharmaceutical, the company achieved a total operating income of 623 million yuan in the first three quarters of 2021, a year-on-year increase of 37.
97%; realized a net profit of 73 million yuan, a year-on-year increase.
an increase of 10.
74%
.
According to the company's 2021 performance forecast data, it is expected to achieve a net profit of 87 million yuan to 97 million yuan for the year, with a year-on-year change range of 9.
97% to 22.
61%
.
As for the reasons for the changes in performance, Panlong Pharmaceutical said that it was mainly due to the increase in sales of the company's self-produced products and the increase in income from the pharmaceutical distribution business
.
In addition to Panlong Pharmaceutical, Guizhou Bailing, Essence Pharmaceutical and other stocks also performed well, with an increase of more than 50%, and the daily limit exceeded 4 times during the period
.
It is understood that from the beginning of 2021 to March 28, 2022, the Chinese Medicine Index (CITIC) increased by 18.
5%, while the overall pharmaceutical index (CITIC) fell by 16.
5% during the same period.
It has become the sub-sector with the largest increase in the pharmaceutical sector
.
In 2022, favorable policies will continue to inject new impetus into the development of traditional Chinese medicine
.
On March 29, the "14th Five-Year Plan" was released, and 10 key tasks were deployed for the work of traditional Chinese medicine during the "14th Five-Year Plan" period
.
Compared with the previous policy, it is more detailed and more maneuverable
.
In this regard, Huaan Securities released a research report pointing out that the Chinese medicine industry has undergone changes driven by the "14th Five-Year Plan" policy
.
CITIC Securities said 2022 will be a critical year for investment in the traditional Chinese medicine sector
.
The market of traditional Chinese medicine is sustainable
.
The agency stated that continuous policy encouragement (including the "14th Five-Year" Chinese Medicine Development Plan announced in March 2022) has brought a relatively certain market space for the release of Chinese medicine companies' performance
.
The mild expectation of the decline in the centralized procurement of Chinese patent medicines, the market expansion of Chinese medicine formula granules, and the positive signals of supporting the innovative development of Chinese medicine from the payment side are expected to bring greater performance flexibility to some leading Chinese medicine companies
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
